← Home / Bristol-Myers Squibb Company (BMY)
Stock Analysis
Bristol-Myers Squibb Company (BMY)
BMY
BMY · Healthcare • Pharma
64.86 +2.79%
Track BMY in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when BMY price is:
52W Range Position
100%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-07-31 11:43 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 64.86. Holding above 58.92 keeps the current thesis intact.
⚖️
✓
Fundamentals
Moderate / Strong
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
58.92
↗
Break Above
Confirmation improves above resistance.
64.86
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 58.92
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
30
●
Financial Results
HIGH
BMY reports financial results
On July 30, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the second quarter of 2026.
8-K Filing • SEC EDGAR
APR
30
●
Financial Results
HIGH
Bristol Myers Squibb Reports First Quarter Financial Results for 2026
Financial Results Reflect Strong Execution and a Strengthened Foundation with Significant Pipeline Milestones Ahead • First quarter revenues increased 3% (+1% Ex-FX) to $11.5 billion ◦ Growth Portfolio revenues increased 12% (+9% Ex-FX) to $6.2 billion • GAAP EPS was $1.31 and non-GAAP EPS was $1.58; Both figures in...
8-K Filing • SEC EDGAR
What's Driving BMY?
📈 Technical recovery is improving
Momentum is Neutral. Watch 64.86 for confirmation and 58.92 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 58.92 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
69.9
Price Chart
BMY — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-30
Fair
Fair valuation
Valuation looks broadly balanced for a mature quality business.
Market Cap
$132.8B
Company size
EV
$167.1B
Debt-adjusted value
P/E
18.3
Reasonable
P/S
2.7
Low sales multiple
P/B
6.6
Balanced
EV/Sales
3.4
Low sales multiple
EV/EBIT
119.2
Very high
P/FCF
11.2
Low multiple
FCF Yield
8.96%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Strong execution with elevated leverage
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Moderate
●
Profitability
Strong
≈
Cash Flow
Positive
⚖
Balance Sheet
Stretched
💵 Revenue
11.49B
≈ Moderate
📈 Net Income
2.68B
↗ Strong
🧮 EPS (Basic)
1.31
↗ Strong
Bristol-Myers Squibb Company
Healthcare • Pharma
Related Opportunities